Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer

HER2 is overexpressed and/or amplified in approximately 20% of breast cancers. It is a clinically aggressive subtype; however, the introduction of targeted therapies has greatly improved survival rates. At JADPRO Live 2022, presenters discussed recent updates to clinical practice for HER2-positive m...

Descripción completa

Detalles Bibliográficos
Autores principales: Beasley, Marcie, Daniel, Brooke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2023
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184838/
https://www.ncbi.nlm.nih.gov/pubmed/37197725
http://dx.doi.org/10.6004/jadpro.2023.14.3.13
_version_ 1785042220731072512
author Beasley, Marcie
Daniel, Brooke
author_facet Beasley, Marcie
Daniel, Brooke
author_sort Beasley, Marcie
collection PubMed
description HER2 is overexpressed and/or amplified in approximately 20% of breast cancers. It is a clinically aggressive subtype; however, the introduction of targeted therapies has greatly improved survival rates. At JADPRO Live 2022, presenters discussed recent updates to clinical practice for HER2-positive metastatic breast cancer, and how to interpret emerging evidence on HER2-low data. They also highlighted best practices for monitoring and managing side effects for patients on these therapies.
format Online
Article
Text
id pubmed-10184838
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-101848382023-05-16 Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer Beasley, Marcie Daniel, Brooke J Adv Pract Oncol Meeting Reports HER2 is overexpressed and/or amplified in approximately 20% of breast cancers. It is a clinically aggressive subtype; however, the introduction of targeted therapies has greatly improved survival rates. At JADPRO Live 2022, presenters discussed recent updates to clinical practice for HER2-positive metastatic breast cancer, and how to interpret emerging evidence on HER2-low data. They also highlighted best practices for monitoring and managing side effects for patients on these therapies. Harborside Press LLC 2023-04 2023-04-01 /pmc/articles/PMC10184838/ /pubmed/37197725 http://dx.doi.org/10.6004/jadpro.2023.14.3.13 Text en © 2023 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Meeting Reports
Beasley, Marcie
Daniel, Brooke
Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer
title Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer
title_full Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer
title_fullStr Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer
title_full_unstemmed Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer
title_short Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer
title_sort advancing the care of women with her2-positive metastatic breast cancer
topic Meeting Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184838/
https://www.ncbi.nlm.nih.gov/pubmed/37197725
http://dx.doi.org/10.6004/jadpro.2023.14.3.13
work_keys_str_mv AT beasleymarcie advancingthecareofwomenwithher2positivemetastaticbreastcancer
AT danielbrooke advancingthecareofwomenwithher2positivemetastaticbreastcancer

Ejemplares similares